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Abstract
The chemokine domain of fractalkine (FKN-CD) binds to the classical RGD-binding site of avb3 and that the resulting ternary
complex formation (integrin-FKN-CX3CR1) is critical for CX3CR1 signaling and FKN-induced integrin activation. However,
only certain cell types express CX3CR1. Here we studied if FKN-CD can activate integrins in the absence of CX3CR1. We
describe that WT FKN-CD activated recombinant soluble avb3 in cell-free conditions, but the integrin-binding defective
mutant of FKN-CD (K36E/R37E) did not. This suggests that FKN-CD can activate avb3 in the absence of CX3CR1 through the
direct binding of FKN-CD to avb3. WT FKN-CD activated avb3 on CX3CR1-negative cells (K562 and CHO) but K36E/R37E did
not, suggesting that FKN-CD can activate integrin at the cellular levels in a manner similar to that in cell-free conditions. We
hypothesized that FKN-CD enhances ligand binding to the classical RGD-binding site (site 1) through binding to a second
binding site (site 2) that is distinct from site 1 in avb3. To identify the possible second FKN-CD binding site we performed
docking simulation of avb3-FKN-CD interaction using avb3 with a closed inactive conformation as a target. The simulation
predicted a potential FKN-CD-binding site in inactive avb3 (site 2), which is located at a crevice between av and b3 on the
opposite side of site 1 in the avb3 headpiece. We studied if FKN-CD really binds to site 2 using a peptide that is predicted to
interact with FKN-CD in site 2. Notably the peptide specifically bound to FKN-CD and effectively suppressed integrin
activation by FKN-CD. This suggests that FKN-CD actually binds to site 2, and this leads to integrin activation. We obtained
very similar results in a4b1 and a5b1. The FKN binding to site 2 and resulting integrin activation may be a novel mechanism
of integrin activation and of FKN signaling.
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Introduction
Fractalkine (FKN, CX3CL1) is a membrane-bound chemokine
of the CX3C family [1,2]. FKN is expressed on the cell surface of
IL-1- and TNFa-activated endothelium as a membrane-bound
form [2]. FKN has an N-terminal chemokine domain (residues 1–
76) [3]. FKN is cleaved by metalloproteinases ADAM-10 (A
Disintegrin And Metalloprotease 10) and ADAM-17 and soluble
FKN is released [4–6]. FKN’s highly selective receptor CX3CR1
(a G-protein coupled receptor, GPCR) is expressed in monocytes,
T cell, NK cells, and neuron [7–13]. Interaction between
membrane-bound FKN and CX3CR1 promotes leukocyte adhe-
sion to endothelium [7,14,15].
Integrins are a family of cell adhesion receptors that recognize
extracellular matrix ligands and cell surface ligands [16]. Activated
integrins support both cell migration and adhesion in a cation-
dependent manner. Upon activation, integrins undergo a series of
conformational changes that result in increased binding affinity for
their respective ligands [17]. FKN enhances cell adhesion through
integrin activation that triggers arrest and firm adhesion. It has
been well established that FKN-mediated integrin activation is
typically mediated by CX3CR1 engagement [15,18–24].
We recently discovered that the chemokine domain of FKN
(FKN-CD) binds to integrins a4b1 and avb3 [25]. The affinity of
FKN-CD binding to avb3 is extremely high as an integrin ligand
(KD=3.0610210 M in Mn2+). FKN-CD binds to the ligand-
binding site common to other known integrin ligands (classical
RGD-binding site). The integrin-binding defective FKN-CD
mutant (the Lys36 to Glu/Arg37 to Glu (K36E/R37E) mutant)
is defective in FKN signaling, while it still binds to CX3CR1.
CX3CR1, FKN-CD, and integrin make a ternary complex
through the direct integrin binding to FKN-CD. We propose a
model in which FKN on endothelial cells binds to leukocytes
through CX3CR1 and integrins (avb3 and a4b1), and in which
integrins are directly involved in FKN signaling and leukocyte
trafficking through binding to FKN-CD. We demonstrated that
K36E/R37E suppressed CX3CR1 signaling (integrin activation)
in a concentration-dependent manner [25], suggesting that K36E/
R37E is a dominant-negative antagonist of CX3CR1.
The expression of CX3CR1 is limited to certain cell types. In
the present study, we studied if FKN-CD can activate integrins in
the absence of CX3CR1. We describe that FKN-CD can activate
avb3 in the absence of CX3CR1, but that this activation requires
the direct binding of FKN-CD to avb3. We hypothesized that
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FKN-CD enhances ligand binding to the classical RGD-binding
site (site 1) through binding to a second binding site (site 2) that is
distinct from site 1 in avb3. We identified a potential FKN-CD-
binding site (site 2), which is located at a crevice between av and
b3 on the opposite side of site 1 in the avb3 headpiece. We
provide evidence that FKN-CD actually binds to site 2, and this
leads to integrin activation. The FKN binding to site 2 and
resulting integrin activation may be a novel mechanism of integrin
activation and of FKN signaling.
Materials and Methods
Materials
K562 erythroleukemia cells, U937 monocytic cells, and Chinese
hamster ovary (CHO) cells were obtained from the American
Type Culture Collection. K562 cells expressing human integrin
avb3 (avb3-K562) [26] were provided by Eric Brown (University
of California, San Francisco, CA). K562 cells expressing human
integrin a4 (a4-K562), CHO cells expressing human integrin b3
(b3-CHO) or integrin a4 (a4-CHO) were described [27].
Recombinant soluble avb3 was synthesized in CHO-K1 cells
using the soluble av and b3 expression constructs and purified by
Ni-NTA affinity chromatography as described [28]. The disin-
tegrin domain of ADAM-15 (GST fusion protein) was synthesized
as described [29]. Fibrinogen c-chain C-terminal domain that
lacks residues 400–411 (cC399tr) was synthesized as described
[30]. GST-fusion proteins of fibronectin type III domains 8–11
(FN8-11), and fibronectin H120 fragment (FN-H120) were
described [25]. We confirmed that these ligands are properly
folded, since heat treatment of the ligands effectively suppressed
their binding to integrins upon stimulation by FKN-CD in the
binding assay (see below)(Figure S1). Vascular cell adhesion
molecule-1 (VCAM-1) was provided by Novartis. Anti-CX3CR1
antibody was purchased from AbD Serotec. Anti-human b3 mAb
AV10 was provided by B. Felding-Habermann (The Scripps
Research Institute, La Jolla, CA). HRP-conjugated anti-His tag
antibody was purchased from Qiagen (Valencia, CA).
Synthesis of FKN-CD
Recombinant FKN-CD (WT and K36E/R37E) were synthe-
sized as described [25] using PET28a expression vector. The
proteins were synthesized in BL21 induced by isopropyl b-D-
thiogalactoside as insoluble proteins. The proteins were solubilized
in 8 M urea, purified by Ni-NTA affinity chromatography under
denatured conditions, and refolded as previously described [31].
The refolded proteins were .90% homogeneous upon SDS-
PAGE.
Synthesis of site 2 peptides
We introduced 6His tag to the BamHI site of pGEX-2T using
59-GATCTCATCATCACCATCACCATG-39 and 59-GATC-
CATGGTGATGGTGATGATGA-39 (resulting vector is desig-
nated pGEX-2T6His). We synthesized GST fusion protein of site
2 peptide (QPNDGQSHVGSDNHYSASTTM, residues 267–287
of b3, C273 is changed to S) and a scrambled site 2 peptide
(VHDSHYSGQGAMSDNTNSPQT) by subcloning oligonucleo-
tides that encodes these sequences into the BamHI/EcoRI site of
pGEX-2T6His. We synthesized the proteins in BL21 cells and
purified using glutathione-Sepharose affinity chromatography.
The corresponding b1, b2, and b4 peptides were generated as
described above.
Binding of soluble avb3 to cC399tr or ADAM-15
ELISA-type binding assays were performed as described
previously [25]. Briefly, wells of 96-well Immulon 2 microtiter
plates (Dynatech Laboratories, Chantilly, VA) were coated with
100 ml PBS containing cC399tr or ADAM-15 for 2 h at 37uC.
Remaining protein binding sites were blocked by incubating with
PBS/0.1% BSA for 30 min at room temperature. After washing
with PBS, soluble recombinant avb3 (5 mg/ml) in the presence or
absence of FKN-CD (WT or K36E/R37E) was added to the wells
and incubated in HEPES-Tyrodes buffer (10 mM HEPES,
150 mM NaCl, 12 mM NaHCO3, 0.4 mM NaH2PO4, 2.5 mM
KCl, 0.1% glucose, 0.1% BSA) with 1 mM CaCl2 for 2 h at room
temperature. After unbound avb3 was removed by rinsing the
wells with binding buffer, bound avb3 was measured using anti-
integrin b3 mAb (AV-10) followed by HRP-conjugated goat anti-
mouse IgG and peroxidase substrates.
Flow cytometry
The cells were cultured to nearly confluent in RPMI 1640/10%
FCS (K562) or DMEM/10% FCS (CHO cells). The cells were
resuspended with RPMI 1640/0.02% BSA or DMEM/0.02%
BSA and incubated for 30 min at room temperature to block
remaining protein binding sites. The cells were then incubated
with WT FKN-CD or K36E/R37E for 5 min at room temper-
ature and then incubated with FITC-labeled integrin ligands
(cC399tr, FN8-11, or FN-H120) for 15 min at room temperature.
For blocking experiments, FKN-CD was preincubated with S2-b3
peptide for 30 min at room temperature. The cells were washed
with PBS/0.02% BSA and analyzed by FACSCalibur (Becton
Dickinson, Mountain View, CA).
Binding of S2 peptide to proteins
ELISA-type binding assays were performed as described
previously [25]. Briefly, wells of 96-well Immulon 2 microtiter
plates (Dynatech Laboratories, Chantilly, VA) were coated with
100 ml PBS containing FKN-CD, cC399tr, FN-H120, or FN8-11
for 2 h at 37uC. GST tag was removed by thrombin digestion for
FN-H120 and FN-8-11. Remaining protein binding sites were
blocked by incubating with PBS/0.1% BSA for 30 min at room
temperature. After washing with PBS, S2 peptides were added to
the wells and incubated in PBS for 2 h at room temperature. After
unbound S2 peptides were removed by rinsing the wells with PBS,
bound S2 peptides (GST-tagged) were measured using HRP-
conjugated anti-GST antibody and peroxidase substrates.
GST Pull-down assays
We incubated the FKN-CD (0.01 mg, with 6His tag) with GST-
tagged S2-b3 or S2-b1 peptide (5 mg) in 100 ml PBS for 2 h at 4uC
and recovered proteins that bound to S2-b3 or S2-b1 peptide with
glutathione-Agarose (sigma) and analyzed the bound proteins by
Western blotting.
Adhesion assays
Adhesion assays were performed as described previously [25].
Briefly, well of 96-well Immulon 2 microtiter plates were coated
with 100 ml PBS containing FN8-11, ADAM-15, and VCAM-1
and were incubated for 2 h at 37uC. Remaining protein binding
sites were blocked by incubating with PBS/0.1% BSA for 30 min
at room temperature. After washing with PBS, K562, avb3-K562,
and a4-K562 cells in 100 ml RPMI 1640 were added to the wells
and incubated at 37uC for 1 h. After unbound cells were removed
by rinsing the wells with the medium used for adhesion assays,
CX3CR1-Independent Integrin Activation by CX3CL1
PLOS ONE | www.plosone.org 2 May 2014 | Volume 9 | Issue 5 | e96372
bound cells were quantified by measuring endogenous phospha-
tase activity.
Docking simulation
Docking simulation of interaction between FKN-CD and
integrin avb3 (closed inactive form) was performed using
AutoDock3 as described [32]. In the present study we used the
headpiece (residues 1–438 of av and residues 55–432 of b3) of
avb3 (1JV2.pdb). Cations were not present in avb3 during
docking simulation, as in the previous studies using avb3 (open
form, 1L5G.pdb) [25,32].
Other methods
Treatment differences were tested using ANOVA and a Tukey
multiple comparison test to control the global type I error using
Prism 5.0 (Graphpad Software).
Results
FKN-CD activates integrins avb3 in cell-free conditions
It has been reported that FKN rapidly enhances cell adhesion
through activating integrins, which is mediated solely by CX3CR1
[7–9]. Is FKN totally inactive in CX3CR1-negative cell types?
This question is biologically relevant since the expression of
CX3CR1 is limited to certain cell types (see Introduction). We first
studied if FKN-CD activates integrins in a CX3CR1-independent
manner using recombinant soluble avb3 in cell-free conditions.
WT FKN-CD markedly enhanced the binding of soluble avb3 (in
1 mM Ca2+ to keep avb3 inactive) to immobilized cC399tr, a
specific ligand to avb3 [30], in a concentration-dependent
manner, but K36E/R37E (the integrin-binding defective FKN-
CD mutant) was defective in this function (Figures 1a and 1b). We
obtained essentially the same results using another avb3-specific
ligand, the disintegrin domain of ADAM-15 [29] (Figure 1c),
suggesting that this phenomenon is not ligand specific. These
results suggest that FKN-CD activates integrins without CX3CR1
in a cell-free condition and this activation requires direct integrin
binding of FKN-CD.
FKN-CD-induced integrin activation occurs in CX3CR1-
negative cells
We studied if FKN-CD activates avb3 at the cellular level in a
CX3CR1-independent manner. It has been reported that K562
cells do not express detectable CX3CR1 mRNA and do not bind
to soluble or membrane-bound FKN, while K562 cells that
express recombinant CX3CR1 robustly bind to FKN [14]. We
also confirmed that CX3CR1 is not detectable in avb3-K562 cells
by western blotting (data not shown). We studied if FKN-CD
induces avb3 activation using K562 cells that express recombinant
avb3 (avb3-K562 cells). To reduce the basal levels of integrin
activation 1 mM Ca2+ was included in the assay medium. The
binding of FITC-labelled cC399tr was measured in flow
cytometry. Interestingly, WT FKN-CD enhanced the binding of
cC399tr to avb3-K562 in a concentration-dependent manner, but
K36E/R37E did not (Figure 2a). The original observation of
Figure 1. FKN-CD activates avb3 integrin in cell-free conditions
(through direct integrin binding). a. Activation of soluble avb3 by
FKN-CD as a function of cC399tr concentration. Binding of soluble avb3
(5 mg/ml) to immobilized cC399tr in the presence or absence of WT
FKN-CD (40 mg/ml) was measured by ELISA. Data are shown as means6
SEM of three independent experiments. b. Activation of soluble avb3 by
FKN-CD as a function of FKN-CD concentration. Binding of soluble avb3
(5 mg/ml) to immobilized cC399tr (100 mg/ml) in the presence or
absence of WT FKN-CD or R36E/R37E was measured by ELISA. Data are
shown as means 6 SEM of three independent experiments. c.
Activation of soluble avb3 by FKN-CD using ADAM-15 as a ligand.
Experiments were done as described in (a), except that ADAM-15 and
20 mg/ml FKN-CD were used. Data are shown as means 6 SEM of three
independent experiments.
doi:10.1371/journal.pone.0096372.g001
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FKN-induced integrin activation is enhanced cell adhesion to
substrate by FKN in a CX3CR1-dependent manner [7]. We
found that FKN-CD can enhance cell adhesion of avb3-K562
cells to ADAM-15 (Figure 2b). These results suggest that FKN-CD
can directly activate avb3 in the absence of CX3CR1 and this
activation can be detected using different binding assays and
different integrin ligands.
Figure 2. FKN-CD activates avb3 integrin on the surface of cells that do not express CX3CR1 (through direct integrin binding). a.
Activation of avb3 by WT FKN-CD, but not by K36E/R37E (integrin-binding defective), in avb3-K562 cells (CX3CR1-negative). Cells were incubated
with FITC-labeled cC399tr in the presence of WT FKN-CD or K36E/R37E. Binding of cC399tr to cells was measured by flow cytometry. Data are shown
as means 6 SEM of median fluorescent intensity (MFI) of three independent experiments. b. avb3 activation by FKN-CD as measured by adhesion to
ADAM-15. Adhesion assays were performed as described in the methods. Data are shown as means 6 SEM of three independent experiments. c.
Activation of avb3 by FKN-CD in b3-CHO cells (CX3CR1-negative). Experiments were performed as described in (a) except that b3-CHO cells (CX3CR1-
negative) were used instead of avb3-K562 cells. Data are shown as means 6 SEM of MFI of three independent experiments. d. Activation of avb3 by
FKN-CD in b3-CHO cells at low FKN-CD concentrations. Experiments were performed as described in (c) except that FKN-CD was used at 0.1 and 1 mg/
ml. Data are shown as means 6 SEM of MFI of three independent experiments.
doi:10.1371/journal.pone.0096372.g002
CX3CR1-Independent Integrin Activation by CX3CL1
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The FKN-induced avb3 activation in avb3-K562 cells may be
cell-type specific. So we performed similar experiments using
another CX3CR1-negative cells. It has been reported that CHO
cells do not express detectable CX3CR1 mRNA and do not bind
to FKN or show intracellular signals in response to FKN (Ca2+
mobilization, MAP kinase activation or AKT activation), while
CHO cells that express recombinant CX3CR1 do [33–35]. We
also confirmed that CX3CR1 is not detectable in b3-CHO cells by
Figure 3. Docking simulation of FKN-CD binding to avb3 with an inactive conformation predicts a new ligand-binding site (site 2). a.
A docking model of FKN-CD-integrin avb3 (active) interaction [25]. The headpiece of ligand-bound form of integrin avb3 (PDB code 1L5G) was used
as a target. The model predicts that FKN-CD (PDB code 1F2L, red) binds to the classical RGD-binding site of the integrin avb3 headpiece (site 1). b. A
docking model of FKN-CD-integrin avb3 (inactive) interaction. The headpiece of an inactive form of integrin avb3 (PDB code 1JV2) was used as a
target. The model predicts the position of the second FKN-CD-binding site (site 2). c. Superposition of two models shows that the positions of two
predicted FKN-CD binding sites are distinct. d. Position of the b3 peptide (267–287, blue) in site 2 (S2-b3). Most of amino acid residues in this peptide
are predicted to interact with FKN-CD (Table 1).
doi:10.1371/journal.pone.0096372.g003
Table 1. Amino acid residues involved in the interaction between FKN-CD and integrin avb3.
FKN-CD av b3
Val5, Thr6, Lys18, His26, Tyr27, Gln28, Gln29, Gln31,
Ala32, Ser33, Cys34, Gly35, Arg37, Pro53, Lys54,
Glu55, Gln56, Trp57, Lys59, Asp60, Ala61, Met62,
Gln63, His64, Asp65, Asp66, Arg67, Gln68
Glu15, Gly16, Ser17, Tyr18, Pro41,
Lys42, Ala43, Asn44, Val51, Glu52,
His91, Ala397, Arg398, Ser399,
Met400, Pro401
Pro160, Val161, Met165, Glu171, Glu174, Asn175, Leu185, Pro186,
Met187, Phe188, Lys191, Lys209, Gln210, Ser211, Gln267, Asp270,
Gln272, Cys273, His274, Val275, Gly276, Ser277, Asp278,
His280, Tyr281, Ser282, Ala283, Thr285, Thr286, Met287
Amino acid residues within 0.6 nm between FKN-CD and avb3 were selected using pdb viewer (version 4.1). Amino acid residues in b3 site 2 peptide (S2-b3) are shown
in bold.
doi:10.1371/journal.pone.0096372.t001
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Figure 4. A peptide derived from the predicted site 2 of avb3 (S2-b3) binds to FKN-CD and suppresses CX3CR1-independent FKN-
CD-induced avb3 activation. a. Binding of S2-b3 peptide to immobilized FKN-CD. The binding of the peptide to immobilized FKN-CD was
measured by ELISA. Data are shown as means 6 SEM of three independent experiments. b. Pull-down assays. FKN-CD (with 6His tag) was incubated
with S2-b3 or S2-b1 peptide (GST fusion protein) and the complexes were analyzed by Western blotting. c. Binding of site 2 peptides from different
integrin b subunits (S2-b1, b2, b3, and b4) to immobilized FKN-CD. The binding of peptides to immobilized FKN-CD was measured as described in (a).
Data are shown as means 6 SEM of three independent experiments. d. Binding of S2-b3 peptide to FKN-CD. The binding of the peptide to
immobilized FKN-CD, cC399tr, FN-H120, FN-8-11 (5 mM) was measured as described in (a). Data are shown as means 6 SEM of three independent
experiments. e. Effect of S2-b3 peptide on FKN-CD induced integrin activation in avb3-K562 cells. Cells were incubated with FITC-labeled cC399tr in
the presence of FKN-CD or the mixture of FKN-CD and S2-b3 peptide. FKN-CD (20 mg/ml) were preincubated with S2-b3 (300 mg/ml) in PBS for 30 min
at room temperature. Binding of FITC-labeled cC399tr to cells was measured by flow cytometry. Data are shown as means 6 SEM of MFI of three
independent experiments. f. Effect of S2-b3 peptide on FKN-CD induced integrin activation in b3-CHO cells. The binding of cC399tr to cells was
measured as described in e). Data are shown as means 6 SEM of MFI of three independent experiments.
doi:10.1371/journal.pone.0096372.g004
CX3CR1-Independent Integrin Activation by CX3CL1
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Figure 5. FKN-CD activates a4b1 integrin in a CX3CR1-independent manner through the binding to site 2. a. Activation of a4b1 by FKN-
CD in a4-K562 cells (CX3CR1-negative). The binding of FITC-labeled H120 (specific ligand to a4b1) to cells was measured by flow cytometry. Data are
shown as means6 SEM of MFI of three independent experiments. b. Adhesion of a4-K562 cell to VCAM-1. Cell adhesion to immobilized VCAM-1 was
CX3CR1-Independent Integrin Activation by CX3CL1
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western blotting (data not shown). Using CHO cells that express
recombinant avb3 (b3-CHO cells), we obtained the results that
are very similar to those of avb3-K562: FKN-CD markedly
enhanced the binding of cC399tr to b3-CHO cells in a
concentration-dependent manner, but K36E/R37E was defective
in this function (Figure 2c). These findings suggest that FKN-CD
induced avb3 activation in a CX3CR1-independent manner is not
cell-type specific. Thus there may be another mechanism of FKN-
CD-induced integrin activation in addition to the well-established
CX3CR1-mediated pathway (inside-out signaling).
FKN is used at 10–100 nM in other studies [15,36,37]
(equivalent to 0.12–1.2 mg/ml FKN-CD). We found that FKN-
CD at 0.1–1 mg/ml induced detectable integrin activation in b3-
CHO cells in the absence of CX3CR1 in our binding assays
(Figure 2d). This suggests that CX3CR1-independent integrin
activation by FKN-CD also occurs at FKN levels that have been
widely used.
Docking simulation predicts that there is a second FKN-
CD binding site in avb3
We demonstrated that FKN-CD activates integrin avb3 in a
CX3CR1-independent manner and K36E/R37E is defective in
this function, suggesting that this activation involves direct avb3-
FKN-CD interaction. If this is the case, since the classical RGD-
binding site may be occupied by avb3 ligands (cC399tr and
ADAM15), it is hypothesized that FKN-CD binds to another
binding site. The crystal structure of the active ligand-bound form
of avb3, however, contains only one RGD-containing peptide
(PDB code 1L5G) [38]. In our previous study, docking simulation
of interaction between FKN-CD and active avb3 predicts that
FKN-CD binds to the classical RGD-binding site [25] (designated
site 1) (Figure 3a). We suspected that the inactive form of avb3, in
which site 1 is in a closed conformation, may have an open second
ligand-binding site. We thus performed another docking simula-
tion of FKN-CD-avb3 interaction using the inactive form of avb3
(PDB code 1JV2) as a target. The simulation identified a second
FKN-CD-binding site (docking energy -24 kcal/mol) (designated
site 2) (Figure 3b), which is distinct from site 1 (Figure 3c). The
predicted site 2 is located at a shallow crevice between av and b3
on the other side of site 1.
A peptide sequence from the predicted site 2 binds to
FKN-CD and suppresses integrin activation by FKN-CD
To test if FKN-CD really interacts with the predicted site 2, we
selected a peptide sequence from site 2 (residues 267–287 of b3,
designated S2-b3 peptide) that is predicted to interact with FKN-
CD (Figure 3d and Table 1). Notably S2-b3 peptide bound to
FKN-CD in a concentration-dependent manner (Figure 4a) and
pulled down FKN-CD from solution (Figure 4b), control parent
GST did not bind to FKN-CD. This indicates that FKN-CD
specifically interacts with the predicted site 2.
Since FKN-CD binds to a4b1 as well [25], we expected that site
2 is present in other integrin species. We generated peptides from
the b1, b2 and b4 subunits that correspond to S2-b3 peptide
(designated S2-b1, b2, and b4, respectively), and compared their
ability to bind to FKN-CD. We studied if these peptides bind to
FKN-CD in ELISA-type binding assays. We found that these
peptides bound to FKN-CD as well, while S2-b3 peptide was the
most effective (Figure 4c). These findings suggest that site 2 is
present in other integrins as well, and FKN-CD is likely to activate
integrins other than avb3.
We studied the binding specificity of S2-b3 peptide to other
integrin ligands used in this study in ELISA-type binding assay.
S2-b3 peptide did not significantly interact with cC399tr, a5b1-
specific ligand fibronectin type III repeats 8-11 (FN8-11), and
a4b1-specific fibronectin fragment H120 [39] (Figure 4d). This
suggests that S2-b3 peptide does not affect the binding of these
integrin ligands. As another control experiment we studied if
FKN-CD directly bind to these integrin ligands in ELISA-type
binding assay. We did not detect significant binding of FKN-CD
to these integrin ligands (data not shown), suggesting that FKN-
CD does not direct bind to these ligands.
We studied if S2-b3 peptide affects FKN-CD-induced activation
of avb3 by measuring the binding of labeled cC399tr in the
presence of FKN-CD in CX3CR1-negative cells. To show more
specificity of S2-b3 peptide, we generated scrambled S2-b3
peptide (S2-b3scr peptide). Notably, S2-b3 peptide suppressed
the cC399tr binding to avb3 increased by FKN-CD in avb3-
K562 cells (Figure 4e) and b3-CHO cells (Figure 4f), but GST or
S2-b3scr peptide did not. These results suggest that FKN-CD
binding to site 2 is involved in FKN-CD-induced CX3CR1-
independent avb3 activation.
FKN-CD activates integrins a4b1 and a5b1 through direct
binding to site 2
We studied if FKN-CD activates integrins other than avb3 in a
CX3CR1-independent manner. We measured the binding of
FITC-labeled H120 to K562 and CHO cells that overexpress
recombinant a4b1 (designated a4-K562 and a4-CHO cells,
respectively) and the adhesion of a4-K562 cells to H120
(Figure 5). We also studied a5b1 activation by FKN-CD using
parent K562 or CHO cells that express a5b1. We measured the
binding of FITC-labeled FN8-11 and cell adhesion to FN8-11
(Figure 6). We obtained very similar results in a4b1 and a5b1 to
that of avb3: WT FKN-CD activated a4b1 and a5b1, but K36E/
R37E did not. FKN-CD at 1 mg/ml or less induced detectable
a4b1 and a5b1 activation. S2-b3 peptide suppressed FKN-CD-
induced a4b1 and a5b1 activation, but control GST or S2-b3scr
peptide did not. These results suggest that WT FKN-CD activates
integrins a4b1 and a5b1 in a CX3CR1-independent manner
through binding to site 2.
measured as described in the methods. Data are shown as means 6 SEM of three independent experiments. c. Effect of S2-b3 on FKN-CD induced
a4b1 activation. a4-K562 cells were incubated with FITC-labeled H120 in the presence of FKN-CD or the mixtures of FKN-CD and S2-b3. FKN-CD
(20 mg/ml) was preincubated with S2-b3 (300 mg/ml) in PBS for 30 min at room temperature. Binding of FITC-labeled H120 to cells was measured by
flow cytometry. Data are shown as means 6 SEM of MFI of three independent experiments. d. Activation of a4b1 by FKN-CD in a4-CHO cells
(CX3CR1-negative) in a CX3CR1-independent manner. The binding of FITC-labeled H120 (specific ligand to a4b1) was measured by flow cytometry.
Data are shown as means 6 SEM of MFI of three independent experiments. e. Activation of a4b1 by FKN-CD in a4-CHO cells at low FKN-CD
concentrations. Experiments were performed as described in (d) except that FKN-CD and K36E/R37E were used at 0.1 and 1 mg/ml. Data are shown as
means 6 SEM of MFI of three independent experiments. f. Effect of S2-b3 peptide on FKN-CD induced integrin activation in a4-CHO cells.
Experiments were performed as descibed in c) except that a4-CHO cells were used. Data are shown as means 6 SEM of MFI of three independent
experiments.
doi:10.1371/journal.pone.0096372.g005
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Discussion
The present study establishes that FKN-CD can activate
integrins avb3, a4b1 and a5b1 in a CX3CR1-independent
manner. We presented evidence that FKN-CD activates soluble
avb3 in cell-free conditions and integrins on the surface of cells
that do not express CX3CR1. We identified a potential
mechanism of CX3CR1-independent integrin activation by
FKN. Docking simulation predicted another FKN-CD binding
site in the closed form of avb3 (site 2) that is distinct from the
classical RGD-binding site (site 1). Notably, a peptide from site 2
(S2-b3) directly bound to FKN-CD and suppressed FKN-CD
induced activation of integrins avb3, a4b1 and a5b1. These
findings suggest that FKN-CD directly binds to the newly
identified site 2, and this interaction potentially induces confor-
mational changes that enhance ligand binding to site 1. We also
showed that peptide sequences corresponding to S2-b3 peptide
from other integrin b subunits bound to FKN-CD. This suggests
that site 2 in other integrin b subunits may also be involved in
FKN-CD-mediated integrin activation. These findings are consis-
tent with the docking model. We did not detect significant binding
of FKN-CD to the ligands in ELISA-type binding assays (data not
shown). It is unlikely that FKN-CD affects the ligands used
(cC399tr, H120, and FN8-11) and enhanced their binding to
integrins. To detect the FKN-CD induced integrin activation we
needed to keep integrin in an inactive state by using assay media
that contain 1 mM Ca2+ or RPMI1640 medium that contains
Ca2+ (approx. 0.4 mM). When avb3 on K562 cells is activated by
1 mM Mn2+, soluble cC399tr bound to avb3 at a maximal level
without FKN-CD, and we did not detect further activation by
FKN-CD or inhibition by S2-b3 peptide (data not shown). This is
consistent with the idea that the direct binding of FKN-CD to site
2 activates integrins that are inactive in the physiological body
fluids that contain high [Ca2+] (1.1–1.4 mM).
We showed that CX3CR1-independent integrin activation by
FKN can be detected at 1 mg/ml FKN-CD or less in our assay
system, suggesting that FKN-CD can induce CX3CR1-indepen-
dent integrin activation in at FKN concentrations widely used in
other studies. We recently reported that FKN-CD has KD of
1028 M to integrin avb3 in the presence of Ca2+ (which reduces
integrin affinity) [25]. Thus it is reasonable that FKN-CD
concentration at 0.1–1 mg/ml (about 8–80 nM) may be required
for FKN to bind to site 2 and activate integrins in the absence of
CX3CR1. It is important to note that FKN is expressed as a
membrane-bound form (e.g., of endothelial cells), unlike other
soluble chemokines, and highly concentrated on the cell surface.
Kinetics of interaction between membrane-bound FKN and
integrins may be different from that between soluble FKN and
integrins. These issues should be addressed in future studies.
We propose that integrins on CX3CR1-negative cells (such as
K562) can be efficiently activated upon binding to membrane-
bound FKN (on endothelial cells) in an CX3CR1-independent
manner. CX3CR1 is not widely expressed (see Introduction).
Interestingly only 2 out of 12 human hematopoietic cell lines tested
express CX3CR1 [15]. Also, 7 breast cancer cell lines, 12
melanoma cell lines tested and their normal counterparts
(mammary epithelial cells and melanocytes) do not express
CX3CR1 [40]. Our results suggest that FKN may induce integrin
activation (and perhaps subsequent phenotype changes) in
CX3CR1-negative cells as well, which have not been recognized
as target cells for FKN.
It has been well established that ligand binding to integrins
induces global and/or local conformation changes in integrins.
Binding of a RGD-mimetic peptide induces changes in the tertiary
structure of avb3 [38] and aIIbb3 [41] in the b3 I-like domain.
RGD or ligand-mimetic peptides activate purified, non-activated
aIIbb3 [42] and avb3 [43]. This process does not require signal
transduction and it appears that RGD or ligand-mimetic peptide
triggers conformational changes that lead to full activation of
integrins. These findings suggest that these peptides enhance
integrin affinity by conformational changes in the headpiece
possibly through additional ligand-binding sites in the integrin
[42]. A previous study suggests that there are two RGD-binding
sites in integrin aIIbb3, and that one binding site acts as an
allosteric site based on binding kinetic studies [44]. Also, another
study suggests that two distinct cyclic RGD-mimetic peptides can
simultaneously bind to distinct sites in aIIbb3, and the estimated
distance between two ligand-binding site is about 6.1 +/2 0.5 nm
[45]. The possible allosteric ligand-binding site has not been
pursued probably because the avb3 structure (ligand occupied,
open) contains only one RGD-binding site [38]. In our docking
model the distance between site 1 and site 2 is about 6 nm. Thus,
the position of site 2 is consistent with the previous report. Based
on previous studies it is likely that the newly identified site 2 has
ligand specificity that overlaps with that of site 1, interacts with
integrin ligands other than FKN-CD (e.g., RGD), and is
potentially involved in integrin regulation in an allosteric
mechanism. It is reasonable to assume that FKN-CD binding to
site 2 induces global conformational changes in integrins. The
open and closed structures of avb3 are superposable, while the
specificity loop undergoes conformational changes (0.1 nm shift)
upon RGD binding to avb3 [38]. It is therefore striking that
docking simulation distinguished open and closed conformations
of avb3. One possibility is that only slight changes in conformation
in the headpeice (e.g., specificity loop) are involved in activation
Figure 6. FKN-CD activates a5b1 integrin in a CX3CR1-independent manner through the binding to site 2. a. Activation of a5b1 by FKN-
CD in K562 cells (CX3CR1-negative). The binding of FITC-labeled FN8-11 (specific ligand to a5b1) was measured as described in the methods. Data are
shown as means 6 SEM of MFI of three independent experiments. b. K562 cells adhesion to FN8-11. Cell adhesion to immobilized FN8-11 was
measured as described in the methods. Data are shown as means 6 SEM of three independent experiments. c. Effect of S2-b3 on FKN-CD induced
integrin activation in K562 cells. Cells were incubated with FITC-labeled FN8-11 in the presence of FKN-CD or the mixtures of FKN-CD and S2-b3. FKN-
CD (20 mg/ml) was preincubated with S2-b3 (300 mg/ml) in PBS for 30 min at room temperature. Binding of FITC-labeled FN8-11 to cells was
measured by flow cytometry. Data are shown as means 6 SEM of MFI of three independent experiments. d. Activation of a5b1 by FKN-CD in CHO
cells (CX3CR1-negative) in a CX3CR1-independent manner. The binding of FITC-labeled FN8-11 (specific ligand to a5b1) was measured by flow
cytometry. Data are shown as means 6 SEM of MFI of three independent experiments. e. Activation of a5b1 by FKN-CD in CHO cells at low FKN-CD
concentrations. Experiments were performed as described in (d) except that FKN-CD and K36E/R37E were used at 0.1 and 1 mg/ml. Data are shown as
means 6 SEM of MFI of three independent experiments. f. Effect of S2-b3 peptide on FKN-CD induced integrin activation in CHO cells. Experiments
were performed as descibed in c) except that CHO cells were used. Data are shown as means 6 SEM of MFI of three independent experiments.
doi:10.1371/journal.pone.0096372.g006
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and inactivation of integrins. It would be interesting to address
these questions in future studies.
Taken together the present study suggests a new mechanism of
integrin activation by chemokine FKN through direct binding to
integrins without inside-out signaling. This does not require
CX3CR1 expression or signal transduction, and may play an
important role in both CX3CR1-negative and -positive cell types.
Thus the ligand-site 2 interaction may be a novel target for drug
discovery and site 2 peptides may have potential as therapeutics.
Supporting Information
Figure S1 Heat treatment suppresses the binding of
ligands to integrins. To confirm that the recombinant integrin
ligands are properly folded, we studied if heat treatment (80uC for
10 min) suppresses the binding functions of the proteins. Cells
were incubated with FITC-labeled ligands (heat-treated or non-
treated) in the presence or absence of WT FKN-CD. Binding of
FITC-labeled ligands to cells was measured by flow cytometry.
Data are shown as means 6 SEM of MFI of three independent
experiments. The data suggest that heat treatment significantly
suppresses the FKN-induced binding of the ligands to integrins,
indicating that the ligands used in this study are properly folded for
integrin binding.
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